Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma | Zendy

Tadeusz Robak | Zendy; Huiqiang Huang | Zendy; Jie Jin | Zendy; Jun Zhu | Zendy; Ting Liu | Zendy; Olga Samoilova | Zendy; Halyna Pylypenko | Zendy; Gregor Verhoef | Zendy; Noppadol Siritanaratkul | Zendy; Evgenii A. Osmanov | Zendy; Julia Alexeeva | Zendy; Juliana Pereira | Zendy; Johannes Drach | Zendy; Jiří Mayer | Zendy; Xiaonan Hong | Zendy; Rumiko Okamoto | Zendy; Lixia Pei | Zendy; Brendan Rooney | Zendy; Helgi van de Velde | Zendy; Franco Cavalli | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

Author(s) -

Tadeusz Robak,

Huiqiang Huang,

Jie Jin,

Jun Zhu,

Ting Liu,

Olga Samoilova,

Halyna Pylypenko,

Gregor Verhoef,

Noppadol Siritanaratkul,

Evgenii A. Osmanov,

Julia Alexeeva,

Juliana Pereira,

Johannes Drach,

Jiří Mayer,

Xiaonan Hong,

Rumiko Okamoto,

Lixia Pei,

Brendan Rooney,

Helgi van de Velde,

Franco Cavalli

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1412096

Subject(s) - bortezomib , mantle cell lymphoma , medicine , vincristine , rituximab , prednisone , cyclophosphamide , oncology , lymphoma , chop , proteasome inhibitor , doxorubicin , chemotherapy , multiple myeloma

The proteasome inhibitor bortezomib was initially approved for the treatment of relapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for vincristine in frontline therapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could improve outcomes in patients with newly diagnosed mantle-cell lymphoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research